the knowledge platform

rash in a child

paediatric rash assessment begins by separating the toxic child with petechiae, purpura, mucosal involvement, or desquamation from the well child with a common viral exanthem

paediatricurgentdermatologicinfectious disease & fevergeneral & constitutional

About This Page

This is a clinician-written, evidence-based guide aligned to the MCC Examination Objectives. It is structured by clinical presentation — the way the MCCQE tests and the way patients actually present. Management reflects current Canadian guidelines (CMA, CFPC, CPS). Always cross-reference with institutional protocols and clinical judgment.

The Bottom Line

  • Rash in a Child is managed by first identifying emergency red flags before considering benign explanations
  • Use the child’s age, appearance, hydration/perfusion, growth/development, and caregiver context to structure the differential
  • The differential diagnosis table is the centrepiece: rule out must-not-miss diagnoses before common self-limited causes
  • Investigations should be targeted rather than broad; avoid low-value tests when the child is well and the pattern is clear
  • Management combines stabilization, cause-specific treatment, safety-netting, and family-centred communication

Approach to the Presentation

Rash in a Child is approached as a paediatric clinical presentation rather than a single diagnosis. The first task is to decide whether the child is unstable or has a red flag. The second is to use age, trajectory, associated symptoms, examination, growth/development, and family context to prioritize must-not-miss diagnoses. Canadian practice should align with CPS, PHAC/NACI, Choosing Wisely Canada, and local provincial/territorial pathways where relevant. Paediatric rash assessment begins by separating the toxic child with petechiae, purpura, mucosal involvement, or desquamation from the well child with a common viral exanthem
Differential Diagnosis
diagnosislikelihoodkey featuresdistinguishing test
Meningococcemia / Sepsismust-not-missFever, toxic appearance, non-blanching petechiae/purpura, leg pain, cold extremitiesClinical emergency; ceftriaxone/cefotaxime without delay
Kawasaki Diseasemust-not-missFever ≥5 days plus conjunctivitis, oral changes, rash, extremity changes, lymphadenopathyClinical criteria, CRP/ESR, echocardiography
Measlesmust-not-missUnimmunized child, fever, cough, coryza, conjunctivitis, Koplik spots, cephalocaudal rashPCR/serology via public health; airborne isolation
SJS/TENmust-not-missDrug exposure, fever, painful dusky rash, mucosal erosions, skin tendernessClinical; urgent dermatology/burns/paediatrics
Anaphylaxismust-not-missUrticaria/angioedema plus respiratory compromise, hypotension, vomitingClinical; IM epinephrine
Viral ExanthemcommonWell child, viral prodrome, blanching maculopapular rashClinical
VaricellacommonPruritic vesicles in different stagesClinical or PCR if needed
Parvovirus B19commonSlapped cheek, lacy reticular rashClinical
Scarlet FevercommonSore throat, fever, sandpaper rash, strawberry tongueThroat swab/rapid strep
IgA Vasculitisless commonPalpable purpura legs/buttocks, abdominal pain, arthralgiaUrinalysis and BP

Red Flags & Key History

Symptoms
Fever with non-blanching petechiae or purpura
Toxic appearance, lethargy, neck stiffness, cold extremities
Mucosal erosions, skin pain, blistering, or desquamation
Fever ≥5 days with conjunctivitis/oral changes/extremity swelling
Cough, coryza, conjunctivitis, unimmunized status or measles exposure
Hives with wheeze, vomiting, hypotension, or angioedema
Typical mild symptoms in a well child with normal hydration/perfusion and reliable follow-up
Signs
Toxic appearance, altered responsiveness, poor perfusion, or respiratory distress
Abnormal growth, hydration, neurological, abdominal, skin, or musculoskeletal findings
Focal signs that localize infection, surgical disease, trauma, or inflammatory disease
Findings inconsistent with the history or developmental stage
Normal examination with stable course and clear benign pattern

Approach to Investigation

First-line
Morphology and blanching assessmentFirst-line assessment for this presentation; interpret in clinical context
Vitals and systemic assessmentHigh-yield initial test or examination component
Immunization, travel, contact and medication historyUse when red flags, dehydration, systemic illness, or diagnostic uncertainty are present
CBC/CRP/blood culture if toxic or non-blanching rashTargeted testing rather than broad screening whenever the child is stable
Second-line
Focused imaging or advanced testingUse when first-line assessment suggests surgical, neurological, infectious, inflammatory, or structural disease
Microbiology or serologyUse when public health, infection control, travel, outbreak, immunocompromise, or treatment decisions depend on organism identification
Serial reassessmentImportant when early disease may not yet declare itself
Targeted screening for mimicsUse when presentation is persistent, recurrent, atypical, or associated with poor growth/development
Specialist
Paediatrics or emergency specialistFor unstable child, diagnostic uncertainty, admission need, or high-risk features
Subspecialty consultationSurgery, neurology, infectious diseases, gastroenterology, nephrology, endocrinology, child protection, or public health depending on presentation
1
Immediate priorities
  • Assess ABCs, vital signs, hydration/perfusion, pain, glucose when relevant, and need for urgent escalation
  • Treat shock, hypoxia, seizures, severe dehydration, suspected sepsis, or surgical abdomen without delay
  • Use age-appropriate analgesia and family-centred communication
2
Targeted management
  • Treat the most likely or confirmed cause using Canadian/local guidance
  • Avoid low-value investigations and therapies in typical benign presentations
  • Arrange appropriate follow-up, reassessment, and return precautions
3
Family and safety-netting
  • Explain expected course, red flags, and when to return
  • Assess caregiver capacity, access to fluids/medications/transport, and social supports
  • Escalate safeguarding concerns according to provincial/territorial law

Complications & Pitfalls

  • Premature closure: do not diagnose a benign condition before red flags are excluded.
  • Age-blind assessment: neonates, infants, school-aged children, and adolescents have different risks.
  • Low-value testing: broad testing can distract from careful history, examination, and targeted investigation.
  • Poor safety-netting: discharge requires explicit return precautions and reliable follow-up.
MCCQE1 Exam Tips
  • 1Fever plus petechiae/purpura is sepsis until proven otherwise
  • 2Measles: cough, coryza, conjunctivitis, Koplik spots, unimmunized, face-to-body rash
  • 3Kawasaki disease: fever ≥5 days plus mucocutaneous signs
  • 4SJS/TEN is painful rash plus mucosal involvement after a drug
  • 5IgA vasculitis requires urine and BP checks
  • 6Varicella lesions in different stages are classic
  • 7CanMEDS health advocate: isolate and notify public health for suspected measles
practicetest your knowledge on rash in a childApply what you've learnt with MCCQE1-style questions from the iatroX Q-Bank — paediatric and beyond.
open q-bank

Verified Sources & References

Public Health Agency of Canada — Canadian Immunization Guide
Canadian Paediatric Society — Management of well-appearing febrile young infants aged ≤90 days
MCC Objectives